Literature DB >> 18757667

Using an intrauterine device in immunocompromised women.

Hyacinth Browne1, Somjate Manipalviratn, Alicia Armstrong.   

Abstract

Intrauterine devices (IUDs) are a viable treatment option for immunocompromised women who need contraception or menses suppression. They may also be an alternative treatment for women who have a contraindication to estrogen use. A review of the literature on IUD use in this population is sparse, but currently available data suggest that immunocompromised women are not at greater risk of developing pelvic infections.

Entities:  

Mesh:

Year:  2008        PMID: 18757667      PMCID: PMC2607525          DOI: 10.1097/AOG.0b013e318183464e

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  12 in total

1.  Effect of intrauterine device use on cervical shedding of HIV-1 DNA.

Authors:  B A Richardson; C S Morrison; C Sekadde-Kigondu; S K Sinei; J Overbaugh; D D Panteleeff; D H Weiner; J K Kreiss
Journal:  AIDS       Date:  1999-10-22       Impact factor: 4.177

2.  Effect of the levonorgestrel-releasing intrauterine system on uterine myomas in a renal transplant patient.

Authors:  Y F Fong; K Singh
Journal:  Contraception       Date:  1999-07       Impact factor: 3.375

3.  Intrauterine contraceptive device failures in renal transplant patients.

Authors:  J Zerner; K L Doil; J Drewry; D A Leeber
Journal:  J Reprod Med       Date:  1981-02       Impact factor: 0.142

Review 4.  Intrauterine device and upper-genital-tract infection.

Authors:  D A Grimes
Journal:  Lancet       Date:  2000-09-16       Impact factor: 79.321

5.  Is the intrauterine device appropriate contraception for HIV-1-infected women?

Authors:  C S Morrison; C Sekadde-Kigondu; S K Sinei; D H Weiner; C Kwok; D Kokonya
Journal:  BJOG       Date:  2001-08       Impact factor: 6.531

6.  A trial of contraceptive methods in women with systemic lupus erythematosus.

Authors:  Jorge Sánchez-Guerrero; América G Uribe; Luisa Jiménez-Santana; Marilú Mestanza-Peralta; Pilar Lara-Reyes; Armando H Seuc; María-del-Carmen Cravioto
Journal:  N Engl J Med       Date:  2005-12-15       Impact factor: 91.245

7.  Comparison of female to male and male to female transmission of HIV in 563 stable couples. European Study Group on Heterosexual Transmission of HIV.

Authors: 
Journal:  BMJ       Date:  1992-03-28

8.  Complications of use of intrauterine devices among HIV-1-infected women.

Authors:  S K Sinei; C S Morrison; C Sekadde-Kigondu; M Allen; D Kokonya
Journal:  Lancet       Date:  1998-04-25       Impact factor: 79.321

9.  Contraceptive practice in women with systemic lupus erythematosus.

Authors:  H A Julkunen; R Kaaja; C Friman
Journal:  Br J Rheumatol       Date:  1993-03

10.  A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus.

Authors:  Elizabeth M Stringer; Christine Kaseba; Jens Levy; Moses Sinkala; Robert L Goldenberg; Benjamin H Chi; Inutu Matongo; Sten H Vermund; Mulindi Mwanahamuntu; Jeffrey S A Stringer
Journal:  Am J Obstet Gynecol       Date:  2007-08       Impact factor: 8.661

View more
  4 in total

1.  Transition Planning: Teaching Sexual Self-Management.

Authors:  Rebecca Gleit; Gary Freed; Emily M Fredericks
Journal:  Contemp Pediatr       Date:  2014-04

2.  Sex-Specific Issues in Inflammatory Bowel Disease.

Authors:  Elizabeth Rosenblatt; Sunanda Kane
Journal:  Gastroenterol Hepatol (N Y)       Date:  2015-09

Review 3.  Drug-Drug Interactions, Effectiveness, and Safety of Hormonal Contraceptives in Women Living with HIV.

Authors:  Kimberly K Scarsi; Kristin M Darin; Catherine A Chappell; Stephanie M Nitz; Mohammed Lamorde
Journal:  Drug Saf       Date:  2016-11       Impact factor: 5.606

Review 4.  Contraceptive use in women with inherited metabolic disorders: a retrospective study and literature review.

Authors:  Jessica I Gold; Nina B Gold; Diva D DeLeon; Rebecca Ganetzky
Journal:  Orphanet J Rare Dis       Date:  2022-02-08       Impact factor: 4.123

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.